Skip to main content

Table 3 The number of patients meeting each response criteria

From: Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome

Criteria

Number of patients (% [95% CI])

Diameter changes


RECIST (≥30% decrease)

3 (14% [3-36%])


MASS (≥20% decrease)

3 (14% [3-36%])


Choi (≥10% decrease)

6 (28% [11-52%])

Density changes


MASS (≥40HU decrease or marked central necrosis)

0 (0%)


Choi (≥15% decrease)

7 (33% [15-57%])

Combined diameter and density criteria


MASS (≥20% diameter decrease, ≥40HU density decrease, or marked central necrosis)

3 (14% [3-36%])


Choi (≥10% diameter decrease of ≥15% density decrease)

11 (52% [30-74%])